display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L1 - all populationmML - L1 - BRAF mutantmML - L1 - BRAF wild
immune chekpoint inhibitors
anti-CTLA-4
tremelimumab A3671009
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib IMspire-170
atezolizumab plus SoC IMspire-150 ...
nivolumab based treatment
nivolumab alone CheckMate 067 ... CheckMate 066
nivolumab followed by ipilimumab CheckMate 064
Immune checkpoint association
nivolumab plus ipilimumab CheckMate 067 ... CheckMate 067 ... CheckMate 069 ... CheckMate 069 ... CheckMate 069 ...
relatlimab plus nivolumab RELATIVITY-047

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons